Vaxart, Inc.

Healthcare

NASDAQ:VXRT · NASDAQ Capital Market

Market Cap $137.97M Beta 1.09 P/E (TTM) 3.6

$0.55 -1.75%

-$0.01 today

52W Low $0.26High $0.84

Vol 0.12M · Avg 0.41M

EPS (TTM) $0.15Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-5.00%

Period High

$0.80

Period Low

$0.30

Latest

$0.55

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Relmada Therapeutics, Inc.

NASDAQ:RLMD

$483.67M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

$146.20M

Immunic, Inc.

NASDAQ:IMUX

$139.74M

Repare Therapeutics Inc.

RPTX

$114.24M

Fortress Biotech, Inc.

NASDAQ:FBIO

$99.82M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

$89.00M

Cibus, Inc.

NASDAQ:CBUS

$60.04M

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

$59.46M

TScan Therapeutics, Inc.

NASDAQ:TCRX

$55.88M

Acrivon Therapeutics, Inc. Common Stock

ACRV

$48.75M

What is the latest VXRT filing?

The latest filing shown is DEFA14A dated Jun 16, 2026.

How many recent filings does VXRT have?

Intrinsic Alpha currently shows 20 recent filings for VXRT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.